Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaLegacy Laboratories

Full company profile

uuid000ggfi

Namestring
PharmaLegacy Laboratories
Legal namestring
PharmaLegacy Research LLC
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, in vivo pharmacology services, drug metabolism pharmacokinetics, animal model studies, preclinical CRO services
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

PharmaLegacy generates revenue through providing preclinical contract research services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Services include in vitro efficacy testing, in vivo pharmacology studies, DMPK, toxicology, PK/PD, and histopathology. Revenue is project-based with contracts for specific studies or comprehensive preclinical programs.

pharmalegacy.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for preclinical studies
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on study type, animal models used, duration, species, and regulatory requirements. Clients contact sales team for quotes. Most models available immediately with rapid study initiation.

pharmalegacy.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BTS Research
Description

A San Diego-based preclinical CRO acquired by PharmaLegacy in September 2024, providing GLP and non-GLP biological services across pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries.

pharmalegacy.com
Core offering1 text field

PharmaLegacy Laboratories is a preclinical contract research organization (CRO) that provides in vitro and in vivo pharmacology services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Its offerings span over 1,500 validated animal models across more than 100 indications, including oncology/immuno-oncology, inflammation/autoimmunity, neuroscience, metabolic, hepatic/renal, cardiovascular, pulmonary, bone/orthopedics, and ophthalmology research. The company supports IND-enabling studies through integrated DMPK, toxicology, PK/PD, histopathology, biomarker, and medical device testing services from facilities in Shanghai and San Diego.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 400+ IND applications supported for clients
+2 more records
Product overview1 text field

PharmaLegacy Laboratories is a preclinical Contract Research Organization (CRO) founded in 2008, providing integrated in vitro and in vivo pharmacology studies. The company operates a platform of laboratory services organized around therapeutic focus areas (Oncology/Immuno-Oncology, Inflammation/Autoimmunity, Neuroscience, Metabolic Diseases, Cardiovascular, etc.) supported by core technical services including In Vitro Efficacy and Safety Testing, DMPK (ADME, PK, Toxicology, Bioanalysis), Non-Human Primate Studies, Histopathology, Biomarker Discovery, and Medical Device Testing. The company has over 1,500 validated animal models across 100+ indications, 380,000 square feet of facility space, capacity for 30,000+ animals, and has supported over 400 IND applications. Following the September 2024 acquisition of BTS Research (adding GLP toxicology services), the company now has expanded laboratory operations in North America (San Diego) alongside its Shanghai headquarters.

Product and service12 records
1In Vitro Efficacy and Safety Testing Services
CategoryIn Vitro Pharmacology Services
Description

Comprehensive in vitro laboratory testing services including kinase/enzyme assays, GPCR assays, cell-based cytotoxicity and immune modulatory assays, ADC evaluation, vaccine evaluation, flow cytometry/FACS analysis, safety assays, and biomarkers/pharmacodynamics analysis. Designed for pharmaceutical and biotechnology R&D teams.

2DMPK (Drug Metabolism and Pharmacokinetics) Services
CategoryDMPK Services
Description

Integrated DMPK services covering ADME (Absorption, Distribution, Metabolism, Excretion), pharmacokinetics, toxicology, and bioanalysis for drug discovery support. Compliant with FDA, EMA, and NMPA regulations with FDA Part 11 compliance.

3In Vivo Animal Model Studies
CategoryIn Vivo Pharmacology Services
Description

Preclinical in vivo pharmacology studies across over 1,500 validated animal models spanning 100+ indications in therapeutic areas including oncology, inflammation, autoimmunity, neuroscience, metabolic diseases, and more. Most models available immediately with studies starting in under two weeks.

4Non-Human Primate (NHP) Studies
CategoryNon-Human Primate Research Services
Description

Specialized non-human primate studies using cynomolgus monkeys for inflammation, immune and autoimmune diseases, hematology and thrombosis, metabolic disease models, ophthalmology, and orthopedics research. NHPs are farm-raised for research use with verified provenance.

5Histopathology Services
CategoryHistopathology Services
Description

Histopathology and histomorphometry analysis services for preclinical studies including cancer pathology, inflammatory pathology, toxicological pathology, and specialized tissue implant analysis.

6Biomarker Discovery and Detection
CategoryBiomarker Services
Description

Biomarker detection services including in vitro immunization, cytokines profiling, molecular biology, and Western blot analysis for preclinical drug development programs.

7Medical Device Testing
CategoryMedical Device Testing Services
Description

Preclinical testing services for medical devices including cardiovascular devices, cerebrovascular devices, bone/dental devices, and doctor-operated devices.

8Oncology / Immuno-Oncology Platform
CategoryOncology Research Services
Description

Comprehensive oncology research services including humanized mouse models (HuCD34+ and HuPBMC), syngeneic mouse models, xenograft mouse models, nude rat models, ex-vivo tumor studies, bone metastasis models, human cancer cell panel, and ADC characterization and evaluation.

9Inflammation, Immunity and Autoimmunity Models
CategoryInflammation Research Services
Description

Animal models for arthritis, allergy/hypersensitivity, colitis, neuroinflammation, uveitis/conjunctivitis, pneumonitis, psoriasis, systemic lupus erythematosus, graft-versus-host disease, sepsis, and general inflammation studies.

10Neuroscience Disease Models
CategoryNeuroscience Research Services
Description

Neurodegenerative disease models including Alzheimer's, Parkinson's, ALS, Huntington's, spinal muscular atrophy, Rett syndrome, and aging studies, plus neuropsychiatric disease models for depression, anxiety, schizophrenia, and addiction.

11Ophthalmology Disease Models
CategoryOphthalmology Research Services
Description

Comprehensive ocular disease models including dry AMD, wet AMD, glaucoma, diabetic retinopathy, dry eye, myopia/presbyopia, ocular gene therapy, and retinal disease models.

12GLP Toxicology Services (BTS Research)
CategoryGLP Toxicology Services
Description

GLP and non-GLP biological services for pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries, added through the BTS Research acquisition.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

Strategic partnership announced October 2024 enables end-to-end drug development solutions combining PharmaLegacy's preclinical expertise with Catawba Research's clinical trial management capabilities. The collaboration provides Catawba Research with new access to China and expanded APAC capabilities while allowing PharmaLegacy to offer comprehensive preclinical and clinical research services.

2BTS Research
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

PharmaLegacy acquired BTS Research, a San Diego-based preclinical CRO, in September 2024. The acquisition expands PharmaLegacy's laboratory footprint in North America, adds GLP toxicology services to its offerings, and strengthens support for global biopharmaceutical clients. BTS Research has roots dating back to 2001.

pharmalegacy.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Frontage is a CRO providing integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process. Partnership enables collaboration on laboratory services supporting drug discovery and development including DMPK, safety and toxicology, and bioanalytical services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Hangzhou Tigermed Consulting Co., Ltd (stock symbol: 300347) is a leading CRO in China providing full clinical trial services since 2004. Partnership enables collaboration across clinical trials with operations in 33 subsidiaries, 63 offices across China, and 12 overseas offices globally.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified clinical and preclinical CRO serving global biopharma. Competes with PharmaLegacy on preclinical pharmacology, safety, and integrated discovery-to-clinical packages, with deeper US footprint and bundled service offerings.

TypeDirect peer
Description

China-based preclinical CRO providing in vivo and in vitro pharmacology, DMPK, and IND-enabling toxicology. Most similar China-domiciled peer to PharmaLegacy in scale and service breadth.

TypeBroad incumbent
Description

Global testing services group with growing preclinical CRO footprint via acquisitions. Provides overlapping in vitro ADME, bioanalytical, and safety testing services to the same biopharma customers as PharmaLegacy.

TypeBroad incumbent
Description

Global leader in preclinical CRO services including animal models, safety assessment, and DMPK. Sets pricing and quality benchmarks in the same preclinical categories where PharmaLegacy competes; broader and better-capitalized.

TypeDirect peer
Description

US-based preclinical CRO offering in vivo toxicology, animal models, and discovery research services. Comparable scale and service mix in GLP toxicology and pharmacology, with a primarily North American sponsor base.

TypeEmerging player
Description

US-based preclinical CRO with focus on biologics, gene therapy, and vaccine testing. Smaller and more focused than PharmaLegacy but competes for biotech preclinical outsourcing dollars in overlapping therapeutic areas.

TypeDirect peer
Description

Global preclinical CRO specializing in oncology and immuno-oncology animal models, including humanized mouse and syngeneic/xenograft platforms. Directly comparable to PharmaLegacy's oncology and I-O indication library.

TypeDirect peer
Description

China-headquartered global CRO offering preclinical in vitro and in vivo services, DMPK, and toxicology at very large scale. Closest direct peer to PharmaLegacy's Shanghai-based preclinical model and the canonical Chinese preclinical CRO benchmark.

TypeDirect peer
Description

US-listed CRO with Chinese roots providing bioanalytical, DMPK, and preclinical services. Already named as a PharmaLegacy partner, it competes for many of the same biopharma sponsors in DMPK and safety assessment.

TypeDirect peer
Description

China-origin, global CRO providing preclinical in vitro/in vivo pharmacology, DMPK, safety assessment, and integrated drug discovery services. Highly comparable business model and customer base to PharmaLegacy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaLegacy Laboratories

Preclinical Contract Research Servicespharmalegacy.com

PharmaLegacy Laboratories firmographics

Firmographics
Name
PharmaLegacy Laboratories
Legal name
PharmaLegacy Research LLC
Website
https://pharmalegacy.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

PharmaLegacy Laboratories industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Preclinical contract research
  • In vivo pharmacology services
  • Drug metabolism pharmacokinetics
  • Animal model studies
  • Preclinical CRO services

Where PharmaLegacy Laboratories is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

PharmaLegacy Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Research Services: PharmaLegacy generates revenue through providing preclinical contract research services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Services include in vitro efficacy testing, in vivo pharmacology studies, DMPK, toxicology, PK/PD, and histopathology. Revenue is project-based with contracts for specific studies or comprehensive preclinical programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for preclinical studies

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

PharmaLegacy Laboratories product offering

Product offering

Core offering

PharmaLegacy Laboratories is a preclinical contract research organization (CRO) that provides in vitro and in vivo pharmacology services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Its offerings span over 1,500 validated animal models across more than 100 indications, including oncology/immuno-oncology, inflammation/autoimmunity, neuroscience, metabolic, hepatic/renal, cardiovascular, pulmonary, bone/orthopedics, and ophthalmology research. The company supports IND-enabling studies through integrated DMPK, toxicology, PK/PD, histopathology, biomarker, and medical device testing services from facilities in Shanghai and San Diego.

Product overview

PharmaLegacy Laboratories is a preclinical Contract Research Organization (CRO) founded in 2008, providing integrated in vitro and in vivo pharmacology studies. The company operates a platform of laboratory services organized around therapeutic focus areas (Oncology/Immuno-Oncology, Inflammation/Autoimmunity, Neuroscience, Metabolic Diseases, Cardiovascular, etc.) supported by core technical services including In Vitro Efficacy and Safety Testing, DMPK (ADME, PK, Toxicology, Bioanalysis), Non-Human Primate Studies, Histopathology, Biomarker Discovery, and Medical Device Testing. The company has over 1,500 validated animal models across 100+ indications, 380,000 square feet of facility space, capacity for 30,000+ animals, and has supported over 400 IND applications. Following the September 2024 acquisition of BTS Research (adding GLP toxicology services), the company now has expanded laboratory operations in North America (San Diego) alongside its Shanghai headquarters.

Differentiator

Problem solved

Functional benefit

Brands

  • BTS Research: A San Diego-based preclinical CRO acquired by PharmaLegacy in September 2024, providing GLP and non-GLP biological services across pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries.

Products and services

  • In Vitro Efficacy and Safety Testing Services Comprehensive in vitro laboratory testing services including kinase/enzyme assays, GPCR assays, cell-based cytotoxicity and immune modulatory assays, ADC evaluation, vaccine evaluation, flow cytometry/FACS analysis, safety assays, and biomarkers/pharmacodynamics analysis. Designed for pharmaceutical and biotechnology R&D teams.
  • DMPK (Drug Metabolism and Pharmacokinetics) Services Integrated DMPK services covering ADME (Absorption, Distribution, Metabolism, Excretion), pharmacokinetics, toxicology, and bioanalysis for drug discovery support. Compliant with FDA, EMA, and NMPA regulations with FDA Part 11 compliance.
  • In Vivo Animal Model Studies Preclinical in vivo pharmacology studies across over 1,500 validated animal models spanning 100+ indications in therapeutic areas including oncology, inflammation, autoimmunity, neuroscience, metabolic diseases, and more. Most models available immediately with studies starting in under two weeks.
  • Non-Human Primate (NHP) Studies Specialized non-human primate studies using cynomolgus monkeys for inflammation, immune and autoimmune diseases, hematology and thrombosis, metabolic disease models, ophthalmology, and orthopedics research. NHPs are farm-raised for research use with verified provenance.
  • Histopathology Services Histopathology and histomorphometry analysis services for preclinical studies including cancer pathology, inflammatory pathology, toxicological pathology, and specialized tissue implant analysis.
  • Biomarker Discovery and Detection Biomarker detection services including in vitro immunization, cytokines profiling, molecular biology, and Western blot analysis for preclinical drug development programs.
  • Medical Device Testing Preclinical testing services for medical devices including cardiovascular devices, cerebrovascular devices, bone/dental devices, and doctor-operated devices.
  • Oncology / Immuno-Oncology Platform Comprehensive oncology research services including humanized mouse models (HuCD34+ and HuPBMC), syngeneic mouse models, xenograft mouse models, nude rat models, ex-vivo tumor studies, bone metastasis models, human cancer cell panel, and ADC characterization and evaluation.
  • Inflammation, Immunity and Autoimmunity Models Animal models for arthritis, allergy/hypersensitivity, colitis, neuroinflammation, uveitis/conjunctivitis, pneumonitis, psoriasis, systemic lupus erythematosus, graft-versus-host disease, sepsis, and general inflammation studies.
  • Neuroscience Disease Models Neurodegenerative disease models including Alzheimer's, Parkinson's, ALS, Huntington's, spinal muscular atrophy, Rett syndrome, and aging studies, plus neuropsychiatric disease models for depression, anxiety, schizophrenia, and addiction.
  • Ophthalmology Disease Models Comprehensive ocular disease models including dry AMD, wet AMD, glaucoma, diabetic retinopathy, dry eye, myopia/presbyopia, ocular gene therapy, and retinal disease models.
  • GLP Toxicology Services (BTS Research) GLP and non-GLP biological services for pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries, added through the BTS Research acquisition.

Quantifiable outcome

  • 400+ IND applications supported for clients
  • +2 more outcomes

Companies that use PharmaLegacy Laboratories

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

PharmaLegacy Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

PharmaLegacy Laboratories partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Catawba ResearchcoreStrategic or Co-development Partner · 22 October 2024Strategic partnership announced October 2024 enables end-to-end drug development solutions combining PharmaLegacy's preclinical expertise with Catawba Research's clinical trial management capabilities. The collaboration provides Catawba Research with new access to China and expanded APAC capabilities while allowing PharmaLegacy to offer comprehensive preclinical and clinical research services.
  • BTS ResearchcoreStrategic or Co-development Partner · 1 September 2024PharmaLegacy acquired BTS Research, a San Diego-based preclinical CRO, in September 2024. The acquisition expands PharmaLegacy's laboratory footprint in North America, adds GLP toxicology services to its offerings, and strengthens support for global biopharmaceutical clients. BTS Research has roots dating back to 2001.
  • FrontageminorStrategic or Co-development PartnerFrontage is a CRO providing integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process. Partnership enables collaboration on laboratory services supporting drug discovery and development including DMPK, safety and toxicology, and bioanalytical services.
  • TigermedminorStrategic or Co-development PartnerHangzhou Tigermed Consulting Co., Ltd (stock symbol: 300347) is a leading CRO in China providing full clinical trial services since 2004. Partnership enables collaboration across clinical trials with operations in 33 subsidiaries, 63 offices across China, and 12 overseas offices globally.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

PharmaLegacy Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Diversified clinical and preclinical CRO serving global biopharma. Competes with PharmaLegacy on preclinical pharmacology, safety, and integrated discovery-to-clinical packages, with deeper US footprint and bundled service offerings.
  • Eurofins Scientific: Global testing services group with growing preclinical CRO footprint via acquisitions. Provides overlapping in vitro ADME, bioanalytical, and safety testing services to the same biopharma customers as PharmaLegacy.
  • Charles River Laboratories: Global leader in preclinical CRO services including animal models, safety assessment, and DMPK. Sets pricing and quality benchmarks in the same preclinical categories where PharmaLegacy competes; broader and better-capitalized.

Direct peers

  • Shanghai Medicilon: China-based preclinical CRO providing in vivo and in vitro pharmacology, DMPK, and IND-enabling toxicology. Most similar China-domiciled peer to PharmaLegacy in scale and service breadth.
  • Inotiv: US-based preclinical CRO offering in vivo toxicology, animal models, and discovery research services. Comparable scale and service mix in GLP toxicology and pharmacology, with a primarily North American sponsor base.
  • Crown Bioscience (JSR Life Sciences): Global preclinical CRO specializing in oncology and immuno-oncology animal models, including humanized mouse and syngeneic/xenograft platforms. Directly comparable to PharmaLegacy's oncology and I-O indication library.
  • Wuxi AppTec: China-headquartered global CRO offering preclinical in vitro and in vivo services, DMPK, and toxicology at very large scale. Closest direct peer to PharmaLegacy's Shanghai-based preclinical model and the canonical Chinese preclinical CRO benchmark.
  • Frontage Holdings: US-listed CRO with Chinese roots providing bioanalytical, DMPK, and preclinical services. Already named as a PharmaLegacy partner, it competes for many of the same biopharma sponsors in DMPK and safety assessment.
  • Pharmaron: China-origin, global CRO providing preclinical in vitro/in vivo pharmacology, DMPK, safety assessment, and integrated drug discovery services. Highly comparable business model and customer base to PharmaLegacy.

Emerging players

  • Bionova Scientific: US-based preclinical CRO with focus on biologics, gene therapy, and vaccine testing. Smaller and more focused than PharmaLegacy but competes for biotech preclinical outsourcing dollars in overlapping therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PharmaLegacy Laboratories social profiles

Digital presence

PharmaLegacy Laboratories compliance and trust

Trust signal

Compliance8 records

PharmaLegacy Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaLegacy Laboratories leadership team

Management profile

Number of profiles

Profiles2 records

PharmaLegacy Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PharmaLegacy Laboratories funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaLegacy Laboratories M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaLegacy Laboratories

What does PharmaLegacy Laboratories do?

PharmaLegacy Laboratories is a preclinical contract research organization (CRO) that provides in vitro and in vivo pharmacology services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Its offerings span over 1,500 validated animal models across more than 100 indications, including oncology/immuno-oncology, inflammation/autoimmunity, neuroscience, metabolic, hepatic/renal, cardiovascular, pulmonary, bone/orthopedics, and ophthalmology research. The company supports IND-enabling studies through integrated DMPK, toxicology, PK/PD, histopathology, biomarker, and medical device testing services from facilities in Shanghai and San Diego.

Is PharmaLegacy Laboratories a public or private company?

PharmaLegacy Laboratories is a private company. It is classified as venture growth investor backed and is currently operating.

When was PharmaLegacy Laboratories founded?

PharmaLegacy Laboratories was founded in 2008. It employs 51 to 100 people.

Where is PharmaLegacy Laboratories based?

PharmaLegacy Laboratories is headquartered in Shanghai, China, in the Asia region.

How does PharmaLegacy Laboratories make money?

One revenue line is on record: contract Research Services.

Who are PharmaLegacy Laboratories's main competitors?

Broad incumbents on record are Labcorp Drug Development (formerly Covance), Eurofins Scientific and Charles River Laboratories. Direct peers are Shanghai Medicilon, Inotiv, Crown Bioscience (JSR Life Sciences), Wuxi AppTec, Frontage Holdings and Pharmaron. Bionova Scientific is listed as an emerging player.

Does PharmaLegacy Laboratories have an API?

No public API is recorded for PharmaLegacy Laboratories.

What industry is PharmaLegacy Laboratories in?

PharmaLegacy Laboratories's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DoNews奥浦迈预计2026年上半年营收增153%- DoNews快讯Aopumai expects H1 2026 revenue of about 450 million yuan, up 153% year-on-year, and net profit of about 124 million yuan, up 229%. The growth is attributed to the inclusion of acquired Pengli Bio in consolidated financials. The forecast is preliminary and unaudited.openPR.comGlobal Drivers Overview: The Rapid Evolution of the Preclinical CRO MarketThe preclinical CRO market is forecast to reach $9.83 billion by 2030, growing at a 9.5% CAGR, driven by demand for precision medicine, rare disease drugs, biologics, and strategic partnerships between pharmaceutical companies and CROs. In September 2024, PharmaLegacy Laboratories, a US-based preclinical drug development CRO, completed the acquisition of BTS Research to expand its in vitro and in vivo service offerings and boost study capacity across North America. BenchSci, a Canada-based AI solutions provider, launched its ASCEND platform in February 2023 to enhance preclinical drug discovery through machine learning analysis.openPR.comSegment Evaluation and Major Growth Areas in the In Vivo Contract Research Organization MarketThe global in vivo contract research organization market is projected to reach $7.77 billion by 2030, growing at a compound annual growth rate of 8.1%, driven by accelerated drug development timelines, advanced disease models, and increased AI-enabled preclinical analytics. In September 2024, China-based PharmaLegacy Laboratories Co. Ltd. finalized the acquisition of BTS Research Inc., a United States-based preclinical CRO, to expand its laboratory footprint in North America and strengthen support for global biopharmaceutical clients. Key growth trends include outsourcing of preclinical research, demand for specialized disease models, and heightened regulatory focus on safety data.PharmalegacyCatawba Research Announces Strategic Partnership With PharmaLegacy Laboratories - PharmaLegacyCatawba Research has announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical research capabilities. This collaboration aims to provide end-to-end drug development solutions and expands Catawba's operational presence in the Asia-Pacific region, specifically China. The joint effort is designed to accelerate the delivery of new therapies by leveraging both entities' specialized expertise.YahooCatawba Research Announces Strategic Partnership With PharmaLegacy LaboratoriesCatawba Research announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical research services. The collaboration expands Catawba's access to China and APAC capabilities, offering end-to-end drug development solutions. The partnership aims to streamline drug development and accelerate new therapies to market.Business Wire BlogCatawba Research Announces Strategic Partnership With PharmaLegacy LaboratoriesCatawba Research announced a strategic partnership with PharmaLegacy Laboratories to combine preclinical and clinical trial services. The collaboration expands Catawba's access to China and APAC capabilities, offering end-to-end drug development solutions. The partnership aims to streamline drug development and accelerate new therapies to market.